NF1 and neurofibroma: Our findings indicate that tumor progression induced by SHP-2 (G503V) and its suppression by BRAP (G370A) may provide the basis for the development of new strategies for the treatment of NF1-MPNST as well as for the prevention of the malignant transformation of neurofibroma in individuals with NF1.